rostaglandin E2 is one of the most studied lipid mediators in inflammation and vascular biology – yet despite decades of research, fully separating the roles of its four receptor subtypes has remained a challenge. EP2, in particular, sits at an interesting crossroads: it couples to cAMP-dependent signaling and contributes to smooth muscle relaxation, airway responses, and inflammatory modulation in tissues where other EP subtypes are also present. That overlap is exactly why a clean, selective pharmacological tool matters. Without one, it is difficult to say whether a given phenotype reflects EP2 specifically or a broader prostanoid effect.
What makes PF-04418948 useful in practice
When researchers need a well-characterized EP2 antagonist, PF-04418948 is one of the most consistently cited options. It blocks the human EP2 receptor with an IC50 of 16 nM and demonstrates over 2000-fold selectivity versus EP1, EP3, EP4, DP1, and CRTH2, while showing minimal interaction across broader GPCR and ion channel panels. That level of selectivity is what makes it genuinely useful – not just as a blocker, but as a tool for asking whether a response is actually EP2-dependent.
In cellular work, the compound suppresses PGE2-driven cAMP elevation, giving a clean functional readout. In isolated tissue, it reverses PGE2-evoked relaxation of mouse trachea with an IC50 of 2.7 nM – a well-validated endpoint in airway and prostanoid biology. These are not just catalog numbers; they represent the kind of consistent, reproducible results that let researchers build on each other’s work.